Pyxis Oncology

Pyxis Oncology FCF Margin

The Free Cash Flow Margin of Pyxis Oncology (PYXS) as of Oct 31, 2026 is -458.30 %. In the previous year, Free Cash Flow Margin was -358.66 % — a change of 27.78% (lower).

FCF Margin

-458.30 %

YoY

27.78%

Last updated:

Free Cash Flow Margin of Pyxis Oncology is 2025 -458.30 % . Free Cash Flow Margin of Pyxis Oncology was 2024 -358.66 % . It decreases by 27.78% lower compared to the previous year.

The Pyxis Oncology FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2024
-358.66 USD
Jan 1, 2025
-458.30 USD
The Pyxis Oncology FCF Margin history
YEARFCF MarginYoY
-458.30 %+27.78%
-358.66 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Pyxis Oncology Stock analysis

What does Pyxis Oncology do? Pyxis Oncology Inc develops a multi-modality portfolio of next-generation therapeutics targeting difficult-to-treat cancers, including antibody drug conjugate (ADC) product candidate PYX-201, immuno-oncology (IO) product candidate PYX-106, and monoclonal antibody (mAb) preclinical discovery programs. The company focuses on developing these as monotherapies and in combination with other therapies to improve patient quality of life. Its ADC product PYX-201 consists of an Immunoglobulin G1 (IgG1) anti-fibronectin Extradomain-B mAb site-specifically conjugated to an auristatin derivative via a cathepsin B-cleavable linker. Pyxis Oncology is developing its product pipeline including PYX-107 as part of its portfolio. The company's revenue model is based on the development and potential future commercialization of its therapeutic candidates. Pyxis Oncology is focused on advancing its pipeline through clinical trials and regulatory approvals. The firm's product candidates are designed to address unmet medical needs in oncology, targeting specific cancer types through innovative mechanisms such as ADC and IO approaches. The company's portfolio includes PYX-201, PYX-106, and PYX-107 as key therapeutic candidates in various stages of development. Pyxis Oncology Inc is a biopharmaceutical company that develops therapeutics for difficult-to-treat cancers. Its product candidates include PYX-201, PYX-106, and PYX-107, each targeting specific cancer mechanisms. The company's development approach combines ADC, IO, and mAb technologies to create innovative cancer treatments. The firm's pipeline focuses on improving patient outcomes through novel therapeutic approaches in oncology. Pyxis Oncology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pyxis Oncology stock

Free Cash Flow Margin of Pyxis Oncology is -458.30 % in 2025.

Free Cash Flow Margin of Pyxis Oncology changed from -358.66 % to -458.30 %, representing a 27.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Pyxis Oncology since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Pyxis Oncology with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Pyxis Oncology

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Pyxis Oncology